Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.91
(
0.61%
)
Bitcoin
66,430.95
(
0.73%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: jq1234 post# 166585

Wednesday, 09/18/2013 9:06:56 AM

Wednesday, September 18, 2013 9:06:56 AM

Post# of 257302
I hadn't seen this one. Do you or Peter have any thoughts on Stem Cell Therapeutics Patent/IP as it relates to Stanford's? SCTPF's CEO recently said that Stanford's patents are particularly broad and might even squeeze out InhibRx. He suggested that this was the reason SCTPF went with the natural ligand to CD47, however, it is unclear to me whether the MOA between the two approaches is really all that different. Any thoughts/comments would be appreciated.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today